Probatebeta
Target

AR

Androgen receptor

As of the edition of 20 October 2026, AR (androgen receptor, UniProt P10275) has 46 drugs tested at it and 60 companies on the list, 10 on route A and 13 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P10275
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
Inside the cell
Solved structures
95
Disease areas
Cancer; Urinary and reproductive; Hormones; Skin and connective tissue; Nervous system; Pregnancy and women's health; Nutrition and metabolism; Inherited and neonatal
Registered trials of its drugs
1,220

Drugs at this target

StatusCount
Marketed24
Active2
Went quiet12
Stopped6
Withdrawn from market1
Status not established1
Total46
DrugStatusFurthest phaseUS protection
EnzalutamideMarketedPhase 4Ends 2027
TestosteroneMarketedPhase 4none listed
BicalutamideMarketedPhase 4none listed
ApalutamideMarketedPhase 4Ends 2033
DarolutamideMarketedPhase 4Ends 2038
AbirateroneMarketedPhase 4none listed
Testosterone undecanoateMarketedPhase 4none listed
FlutamideMarketedPhase 4none listed
Testosterone cypionateMarketedPhase 4none listed
RezvilutamideActivePhase 3none listed
DanazolMarketedPhase 3none listed
ClascoteroneMarketedPhase 4none listed

12 of 46 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A10
Route B13
Engaged14
Undetermined23
Total on the list60
Three companies on route A or B, with the route only
CompanyRoute
AstellasRoute B
AstraZenecaRoute B
Cheplapharm ArzneimittelRoute B

The other 57 companies at AR

In the product

60 companies in all; 57 are not named here, and no score is.

See the 60 companies at AR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at AR

Other targets in cancer

Companies holding approvals at AR